Day Pitney remains committed to providing quality legal counsel, while protecting our clients and employees, and transforming our communities into more just, equal and equitable spaces. For more information, please visit our COVID-19 Resource Center | Racial Justice and Equity Task Force.

News

In the News Press Release

Republicans Seek Probe Into EpiPen Medicaid Rebate Status

Publisher: Bloomberg BNA's Health Care Daily Report
September 14, 2016

Eric Fader was quoted in an article, "Republicans Seek Probe Into EpiPen Medicaid Rebate Status," in Bloomberg BNA's Health Care Daily Report. The article is about how a group of congressional Republicans are asking that the Centers for Medicare & Medicaid Services (CMS) be investigated after it "persistently" classified Mylan's EpiPen as a generic drug under the Medicaid rebate program rather than as a branded drug. Fader explained that the difference between what CMS received from Mylan in rebates and what it should have received is enormous. "It seems clear to me that certain people at CMS have been asleep at the switch on this matter, with other manufacturers' drugs as well as with EpiPen," Fader said, adding that CMS will have to address the issue with Congress.


Recommended
Related Professionals
New York, NY
T: (212) 297 2413